Welcome to our dedicated page for WillScot Holdings SEC filings (Ticker: WSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering if WillScot鈥檚 modular fleet is still running at record utilization or if executives are loading up on shares ahead of the busy construction season? This SEC filings hub brings every disclosure鈥攆rom a single Form 4 to the 300-page 10-K鈥攊nto one streamlined view.
Type a question like 鈥淲illScot insider trading Form 4 transactions鈥� or 鈥淗ow do I read the WillScot quarterly earnings report 10-Q filing?鈥� and our AI surfaces the exact pages that detail unit count, rental rates and backlog. AG真人官方-time feeds pull each 8-K the moment it hits EDGAR, so 鈥淲illScot 8-K material events explained鈥� is no longer a hunt through PDFs.
Here鈥檚 how investors use the page:
- Track WillScot executive stock transactions Form 4 with instant email or SMS alerts.
- Compare segment revenue using an AI summary of every WillScot annual report 10-K simplified.
- Dive into cash-flow drivers with a side-by-side WillScot earnings report filing analysis for consecutive 10-Qs.
- Review the WillScot proxy statement executive compensation to see incentive alignment.
Each document comes with an AI-powered synopsis that translates accounting jargon into plain language鈥攅xactly what 鈥渦nderstanding WillScot SEC documents with AI鈥� should feel like. Whether you need WillScot Form 4 insider transactions real-time, a concise brief on the latest 8-K, or deep context around debt covenants, Stock Titan keeps the entire set of WillScot SEC filings explained simply and updated the second they post.
On 29 Jul 2025, Identiv (INVE) director James E. Ousley reported the acquisition of 28,701 common shares via a grant of Restricted Stock Units (RSUs) under the company鈥檚 2011 Incentive Compensation Plan. The RSUs vest 1/12 each month beginning 1 Jun 2025; vested shares will be delivered on the earlier of (i) three years from the vesting start date or (ii) separation from service. The grant was booked at $0.00, indicating it is part of routine director compensation rather than an open-market purchase. Following the transaction, Ousley鈥檚 direct beneficial ownership rises to 285,456 shares, of which 26,310 are still unvested RSUs. No derivative transactions were reported. The filing shows continued equity alignment between the director and shareholders but does not involve immediate cash outlay or signal a change in company fundamentals.
PROS Holdings (NYSE: PRO) Q2 2025 Form 10-Q highlights
- Top-line growth: Total revenue rose 8% YoY to $88.7 million, driven by a 12% jump in subscription revenue to $73.3 million. Recurring revenue (subscription + maintenance) represented 86% of total sales.
- Margin expansion: Overall gross margin improved two points to 67%. Subscription gross margin reached 79% (up 1 ppt) due to cloud-infrastructure efficiency.
- Profitability trend: Net loss narrowed to $1.8 million (-$0.04 basic EPS) from $7.4 million (-$0.16). Operating loss was roughly flat at $7.6 million.
- Cash & liquidity: Cash and equivalents increased to $179.0 million from $162.0 million at year-end; operating cash flow turned positive at $4.4 million (vs. $1.8 million).
- Debt actions: Exchanged $186.9 million of 2.25% 2027 notes for new 2.5% 2030 notes and sold an additional $50 million of 2030 notes; recorded a $4.2 million extinguishment gain and purchased capped calls that effectively raise the conversion price to $30.34 per share.
- Balance sheet: Total assets $443.0 million; total liabilities $527.9 million; stockholders鈥� deficit widened to $84.9 million mainly from share-based compensation and capped-call premium.
- Retention & mix: Gross revenue retention remained above 93%; U.S. accounted for 36% of revenue, Europe 30%, Rest-of-World 34%.
Management cites continued macro uncertainty but notes improving subscription mix, higher gross margins and stronger cash generation as key progress toward profitability.
Lemonade, Inc. (LMND) 鈥� Form 4 insider filing
CFO Timothy E. Bixby exercised 7,000 fully-vested employee stock options at an exercise price of $23.69, then sold the same 7,000 shares under a Rule 10b5-1 plan. The sales occurred on 18 Jul 2025 (6,000 sh. at $42.50) and 21 Jul 2025 (1,000 sh. at $42.70), generating gross proceeds of roughly $0.30 million versus an aggregate exercise cost of about $0.17 million.
After the transactions Mr. Bixby鈥檚 direct holding remains 263,393 common shares, unchanged from the level prior to the option exercises. He also retains 30,000 shares held indirectly through the Timothy E. Bixby Family Trust and 277,300 unexercised options expiring 25 Sep 2029.
The activity represents <0.02 % of LMND鈥檚 67 million outstanding shares and appears routine portfolio diversification rather than a signal about business fundamentals. No other insiders transacted and no company cash was involved.
Medicus Pharma Ltd. (NASDAQ: MDCX) has entered into a definitive share-exchange agreement to acquire 100% of privately held Antev Limited. The transaction, signed 29 June 2025 and disclosed via Form 8-K, will be executed through the issuance of 2,666,600 new Medicus common shares, representing roughly 17% of Medicus鈥� post-deal outstanding equity ("Consideration Shares"). The shares will carry resale restrictions, a staggered lock-up schedule and a 36-month voting agreement in favour of current Medicus management, limiting immediate market float impact.
In addition, Antev securityholders may earn up to US$65 million in contingent consideration tied to the achievement of U.S. FDA Phase 2 and New Drug Application milestones for Teverelix, Antev鈥檚 lead GnRH antagonist targeting high-risk prostate-cancer and acute urinary-retention markets. No cash is payable at closing, preserving Medicus鈥� balance-sheet liquidity.
The deal is expected to close before the end of August 2025, subject to customary shareholder, regulatory and third-party approvals. The company cautions that closing is not assured. Antev broadens Medicus鈥� pipeline into men鈥檚-health therapeutics; Teverelix is positioned as a potential first-in-class therapy for cardiovascular high-risk prostate-cancer patients. Full terms, lock-up mechanics and registration-rights details are contained in the Share Exchange Agreement (Exhibit 2.1).
Investors should weigh the strategic upside of adding a late-clinical asset against 17% equity dilution, regulatory risk and up to US$65 million in future earn-outs. No immediate revenue, earnings or cash-flow figures for Antev were disclosed, leaving the transaction鈥檚 financial accretion unknown.
FAQ
What is the current stock price of WillScot Holdings (WSC)?
What is the market cap of WillScot Holdings (WSC)?
What is the primary focus of WillScot Holdings?
What range of products and services does the company offer?
Which industries benefit from WillScot's solutions?
How does WillScot differentiate itself from competitors?
What is the significance of modular construction in WillScot's business model?
How does the company ensure operational efficiency and quality?
What should investors know about WillScot's market position?
